Magnificamide Is a New Effective Mammalian α-Amylase Inhibitor

O V Sintsova; E V Leychenko; I N Gladkikh; A P Kalinovskii; M M Monastyrnaya; E P Kozlovskaya

doi:10.1134/S1607672919060097

Magnificamide Is a New Effective Mammalian α-Amylase Inhibitor

Dokl Biochem Biophys. 2019 Nov;489(1):385-387. doi: 10.1134/S1607672919060097. Epub 2020 Mar 4.

Authors

O V Sintsova¹, E V Leychenko², I N Gladkikh², A P Kalinovskii^{2

3}, M M Monastyrnaya², E P Kozlovskaya²

Affiliations

¹ Elyakov Pacific Institute of Bioorganic Chemistry, Far Eastern Branch, Russian Academy of Sciences, 690022, Vladivostok, Russia. sintsova0@gmail.com.
² Elyakov Pacific Institute of Bioorganic Chemistry, Far Eastern Branch, Russian Academy of Sciences, 690022, Vladivostok, Russia.
³ School of Natural Sciences, Far Eastern Federal University, 690091, Vladivostok, Russia.

PMID: 32130606
DOI: 10.1134/S1607672919060097

Abstract

Recombinant analogue of the sea anemone Heteractismagnifica peptide was obtained, and the kinetic parameters of its interaction with mammalian α-amylases were determined. Magnificamide inhibits α-amylases significantly stronger than the medical drug acarbose (Precose^TM or Glucobay^TM). Magnificamide is assumed to find application as a drug for prevention and treatment of metabolic disorders and type 2 diabetes mellitus.

MeSH terms

Amino Acid Sequence
Animals
Enzyme Inhibitors / chemistry
Enzyme Inhibitors / pharmacology*
Peptides / chemistry
Peptides / pharmacology*
Sea Anemones / chemistry
alpha-Amylases / antagonists & inhibitors*

Substances

Enzyme Inhibitors
Peptides
alpha-Amylases